IMNN

{
  "claims": [
    {
      "claim": "Ovarian cancer is a lethal gynecological malignancy with high five-year mortality.",
      "category": "social",
      "quote": "Ovarian cancer is the most lethal of gynecological malignancies among women with more than 60% of women dying within five years of diagnosis.",
      "quantified": true,
      "metric": "five-year mortality rate",
      "quote_verified": true
    },
    {
      "claim": "The annual U.S. burden of ovarian cancer includes about 20,000 new cases and 13,000 deaths.",
      "category": "social",
      "quote": "There were approximately 20,000 new cases of ovarian cancer in the U.S. in 2021 with an estimated 13,000 deaths.",
      "quantified": true,
      "metric": "new cases and deaths in 2021",
      "quote_verified": true
    },
    {
      "claim": "Five-year survival rates for advanced ovarian cancer are low, indicating unmet need.",
      "category": "social",
      "quote": "With the five-year survival rates for Stages III and IV at 41% and 20%, respectively, there remains a need for a therapy that not only reduces the recurrence rate but also meaningfully improves overall survival.",
      "quantified": true,
      "metric": "five-year survival rates by stage",
      "quote_verified": true
    },
    {
      "claim": "Many newly discovered pathogenic viruses lack prophylactic vaccines, highlighting an urgent public health need.",
      "category": "social",
      "quote": "Since 1980, more than 80 pathogenic viruses have been discovered, yet fewer than 4% have a commercially available prophylactic vaccine.",
      "quantified": true,
      "metric": "virus discovery and vaccine availability percentages",
      "quote_verified": true
    },
    {
      "claim": "Vaccines addressing multiple viral strains are a public health need.",
      "category": "social",
      "quote": "There is a clear public health need for vaccines today that address more than one strain of viruses, like COVID-19, which have fast evolving variant capability to offer the widest possible protection.",
      "quantified": false,
      "metric": null,
      "quote_verified": true
    },
    {
      "claim": "The polymer delivery system is biocompatible and reduces the risk of adverse immune response.",
      "category": "social",
      "quote": "The biocompatibility of these polymers reduces the risk of adverse immune response, thus allowing for repeated administration.",
      "quantified": false,
      "metric": null,
      "quote_verified": true
    },
    {
      "claim": "IMNN-001 was well tolerated with no dose-limiting toxicities in the OVATION 1 Study.",
      "category": "social",
      "quote": "IMNN-001 was well tolerated, and no dose-limiting toxicities were detected in the OVATION 1 Study.",
      "quantified": false,
      "metric": null,
      "quote_verified": true
    },
    {
      "claim": "IMNN-001 plus chemotherapy was generally well tolerated with no serious immune-related adverse events.",
      "category": "social",
      "quote": "Treatment was also generally well tolerated, with no reports of cytokine release syndrome or any other serious immune-related adverse events.",
      "quantified": false,
      "metric": null,
      "quote_verified": true
    },
    {
      "claim": "IMNN-001 continued to show a favorable safety profile with no serious immune-related adverse events.",
      "category": "social",
      "quote": "IMNN-001 was generally safe and well tolerated, with no reports of cytokine release syndrome, systemic toxicity or serious immune-related adverse events.",
      "quantified": false,
      "metric": null,
      "quote_verified": true
    },
    {
      "claim": "IMNN-101 was safe and well tolerated in a Phase 1 trial.",
      "category": "social",
      "quote": "Results demonstrated that IMNN-101 is safe and well-tolerated with no serious adverse effects.",
      "quantified": false,
      "metric": null,
      "quote_verified": true
    }
  ],
  "gap_ratio": 0.6,
  "quotes_discarded_unverified": 4,
  "method": "LLM extraction, every claim quote-verified against the filing"
}

{
  "icr_by_year": {
    "2025-12-31": null,
    "2024-12-31": null,
    "2023-12-31": -106.71,
    "2022-12-31": -4.956
  },
  "consecutive_years_below_1": 2,
  "altman_z_double_prime": -59.289,
  "definitions": {
    "zombie": "ICR<1 for 3+ consecutive FYs (BIS 2018)",
    "z_distress": "<1.1 distress, 1.1-2.6 gray, >2.6 safe"
  },
  "inputs": {
    "ebit_t": -21030430,
    "interest_expense_t": 197080
  },
  "stale": true,
  "latest_filing_period": "2025-12-31",
  "source": {
    "url": "https://www.sec.gov/Archives/edgar/data/749647/000149315225008460/0001493152-25-008460-index.htm",
    "form": "10-K",
    "filed": "2025-02-27"
  }
}